Cargando…

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness

BACKGROUND: Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the concept of treatment in hematological malignancies. In comparison with pediatric patients, where responses are maintained over many years, older patients, such as those with non-Hodgkin’s lymphoma (NHL) and multiple my...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachiller, Mireia, Perez-Amill, Lorena, Battram, Anthony Matthew, Carné, Sebastian Ciro, Najjar, Amer, Verhoeyen, Els, Juan, Manel, Urbano-Ispizua, Alvaro, Martin-Antonio, Beatriz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388291/ https://www.ncbi.nlm.nih.gov/pubmed/34433634 http://dx.doi.org/10.1136/jitc-2021-002866

Ejemplares similares

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)

Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
por: Moreno-Castaño, Ana Belen, et al.
Publicado: (2023)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy
por: He, Huan, et al.
Publicado: (2021)

Automated, scaled, transposon-based production of CAR T cells
por: Lock, Dominik, et al.
Publicado: (2022)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6
por: Lee, Young Eun, et al.
Publicado: (2023)

AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
por: Mehra, Vedika, et al.
Publicado: (2023)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
por: Gargett, Tessa, et al.
Publicado: (2022)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
por: Nalawade, Saisha A, et al.
Publicado: (2021)

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
por: Schoutrop, Esther, et al.
Publicado: (2023)

Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
por: Fang, Karen Kai-Lin, et al.
Publicado: (2023)

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
por: Mandriani, Barbara, et al.
Publicado: (2022)

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
por: Martín-Otal, Celia, et al.
Publicado: (2022)

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy
por: Pennell, Christopher A, et al.
Publicado: (2022)

Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function
por: Kumar, Jitendra, et al.
Publicado: (2021)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
por: Zhang, Boning, et al.
Publicado: (2020)

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
por: Abdin, Shifaa M., et al.
Publicado: (2021)

Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
por: Sun, Ming, et al.
Publicado: (2023)

CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
por: Turicek, David P, et al.
Publicado: (2023)

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
por: Wen, Jingjing, et al.
Publicado: (2023)

Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
por: Kuo, Yi-Chiu, et al.
Publicado: (2022)

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
por: Temple, William C, et al.
Publicado: (2023)

Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources
por: Schmidts, Andrea, et al.
Publicado: (2020)

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
por: Quintarelli, Concetta, et al.
Publicado: (2021)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
por: McKenna, Mary K, et al.
Publicado: (2023)

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
por: Roselli, Emiliano, et al.
Publicado: (2021)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
por: Tokatlian, Talar, et al.
Publicado: (2022)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
por: Sun, Luan, et al.
Publicado: (2021)

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression
por: Mueller, Katherine P, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nqvkk2kqrifbdbhgda9ar5qb5t